BIGG

Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Use of Serogroup B Meningococcal (MenB) Vaccines in Persons at Increased Risk for Serogroup B Meningococcal Disease

MMWR recomm. rep; 64 (22), 2015
Ano de publicação: 2015

In October 2014, the Food and Drug Administration (FDA) licensed the first serogroup B meningococcal (MenB) vaccine (MenB-FHbp [Trumenba®, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., Philadelphia, Pennsylvania]) as a 3-dose series. The FDA licensed a second MenB vaccine (MenB-4C [Bexsero®, Novartis Vaccines, Siena, Italy]) in January 2015 as a 2-dose series. Both vaccines were approved for use in persons aged 10 through 25 years. Evidence of benefits and harms were reviewed in accordance with GRADE methods[1]. The primary policy question was “Should MenB vaccines be administered routinely to all persons aged ≥10 years at increased risk for serogroup B meningococcal disease or at increased risk for serogroup B disease because of an outbreak?”